.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202155

« Back to Dashboard
NDA 202155 describes ELIQUIS, which is a drug marketed by Bristol Myers Squibb and is included in one NDA. It is available from three suppliers. There are three patents protecting this drug. Additional details are available on the ELIQUIS profile page.

The generic ingredient in ELIQUIS is apixaban. There are twenty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the apixaban profile page.

Summary for NDA: 202155

Tradename:
ELIQUIS
Applicant:
Bristol Myers Squibb
Ingredient:
apixaban
Patents:3
Formulation / Manufacturing:see details

Pharmacology for NDA: 202155

Mechanism of ActionFactor Xa Inhibitors

Suppliers and Packaging for NDA: 202155

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ELIQUIS
apixaban
TABLET;ORAL 202155 NDA E.R. Squibb & Sons, L.L.C. 0003-0893 0003-0893-21 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0003-0893-21)
ELIQUIS
apixaban
TABLET;ORAL 202155 NDA E.R. Squibb & Sons, L.L.C. 0003-0893 0003-0893-31 10 BLISTER PACK in 1 CARTON (0003-0893-31) > 10 TABLET, FILM COATED in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2.5MG
Approval Date:Dec 28, 2012TE:RLD:No
Patent:9,326,945Patent Expiration:Feb 24, 2031Product Flag?YSubstance Flag?Delist Request?
Regulatory Exclusivity Expiration:Aug 21, 2017
Regulatory Exclusivity Use:INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
Regulatory Exclusivity Expiration:Aug 21, 2017
Regulatory Exclusivity Use:INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc